Novartis Divests Non-Core OTCs, Realigns Consumer Supply Chain
This article was originally published in The Tan Sheet
Executive Summary
Novartis sells six OTC brands, including Bufferin, to focus resources on core consumer health products. The firm also is realigning its consumer health supply chain, including restructuring its Lincoln, Nebraska, manufacturing plant, where the workforce will be cut 40%.
You may also be interested in...
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls
FDA inspectors were in Novartis Consumer Health’s Lincoln, Neb., plant in December and January, as the company was deciding to halt production and recall products. An inspection report notes 10 observations – eight of them repeats from FDA’s visit in mid-2011.
Pfizer's Sturman Succeeds Lil' Drug Store's DeWolf As CHPA Board Chair
Pfizer Consumer Healthcare President and General Manager Paul Sturman takes the reins as chairman of the Consumer Healthcare Products Association's board, announced outgoing chairman Chris DeWolf, president and CEO of Lil' Drug Store.